FBXO40 Activators
FBXO40 Activators are molecules that enhance the activity of the FBXO40 protein, a member of the F-box protein family. This family of proteins is crucial for the regulation of proteasomal degradation of specific substrates by acting as part of the SCF (SKP1-cullin-F-box) complex, which confers substrate specificity. The activators of FBXO40 are involved in fine-tuning the protein's function through various biochemical mechanisms that ensure the proper turnover of substrates implicated in muscle differentiation and growth. Some activators may work by stabilizing the FBXO40 protein, allowing it to more effectively participate in the ubiquitination of its target proteins. Others might enhance the interaction between FBXO40 and its substrate proteins, thereby increasing the efficiency of the SCF complex-mediated ubiquitination process. These activators are not just stabilizers of the protein's structure but may also play a role in modulating the affinity between FBXO40 and its E2 enzyme partners, promoting the transfer of ubiquitin.
Moreover, the activators can influence the localization of FBXO40 within the cell, ensuring that it is present in the areas where its substrates are located, such as the muscle fibers where it regulates protein turnover during muscle differentiation. Some of these molecules may also upregulate the expression of key co-factors required for the SCF complex assembly, indirectly increasing the functional capacity of FBXO40. The direct activators are compounds that could bind to FBXO40 and induce conformational changes that enhance its activity, possibly by exposing the protein's active site more effectively or by facilitating the recruitment of ubiquitin-loaded E2 enzymes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin elevates intracellular cAMP levels, which, through the activation of PKA, can enhance the ubiquitination activity of FBXO40 due to PKA's ability to phosphorylate substrates that could be recognized by FBXO40. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin acts as a calcium ionophore, increasing intracellular calcium levels, which can affect calcineurin activity. Calcineurin influences NFAT signaling, and through this pathway, FBXO40's role in muscle differentiation could be enhanced. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases which increases cAMP by preventing its breakdown, potentially enhancing FBXO40's ubiquitination activity in a manner similar to Forskolin, via PKA pathway activation. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol is a beta-adrenergic agonist that increases cAMP levels in cells, thereby activating PKA. PKA-mediated phosphorylation events may enhance FBXO40's substrate recognition or ubiquitin ligase activity. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $65.00 $280.00 $400.00 | 48 | |
AICAR activates AMPK, which is involved in cellular energy homeostasis. The activation of AMPK can influence various signaling pathways, potentially enhancing the activity of FBXO40 in metabolic regulation. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a PKC activator that can modulate multiple signaling pathways. PKC activation can lead to downstream effects that may enhance FBXO40's role in protein degradation through ubiquitination. | ||||||
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $91.00 $139.00 $374.00 | 36 | |
Dexamethasone acts as a glucocorticoid receptor agonist which can influence muscle protein synthesis and degradation, potentially altering FBXO40 activity related to muscle atrophy. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $120.00 $326.00 $634.00 $947.00 $1259.00 | 38 | |
Rosiglitazone is a PPAR-gamma agonist, which modulates lipid and glucose metabolism. Activation of PPAR-gamma could enhance FBXO40's regulatory role in metabolic processes. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid activates retinoic acid receptors, influencing gene expression. This activation can modulate cellular differentiation processes in which FBXO40 is implicated. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
LiCl inhibits GSK-3beta, leading to Wnt pathway activation. While FBXO40 is not directly part of the Wnt pathway, the modulation of GSK-3beta activity could indirectly enhance FBXO40's function in muscle tissue homeostasis. | ||||||